<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-145193" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sclerotherapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Beneat</surname>
            <given-names>Amanda</given-names>
          </name>
          <aff>New York University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oropallo</surname>
            <given-names>Alisha</given-names>
          </name>
          <aff>Zucker Hofstra Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amanda Beneat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alisha Oropallo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-145193.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sclerotherapy is a group of techniques characterized by the injection of&#x000a0;an irritating substance into a blood vessel to damage the vessel endothelium, induce inflammation with subsequent endofibrosis, and destroy the vessel.<xref ref-type="bibr" rid="article-145193.r1">[1]</xref><xref ref-type="bibr" rid="article-145193.r2">[2]</xref><xref ref-type="bibr" rid="article-145193.r3">[3]</xref>&#x000a0;The irritating substances are termed sclerosing agents and include osmotic agents such as glycerin and hypertonic saline, detergents like polidocanol and sodium tetradecyl sulfate (STS), and iodinated substances.<xref ref-type="bibr" rid="article-145193.r2">[2]</xref><xref ref-type="bibr" rid="article-145193.r4">[4]</xref>&#x000a0;Sclerotherapy is most commonly a primary or adjunctive therapy for cosmetically distressing or symptomatic venous varicosities of the lower extremities, but it also may be employed when treating certain hemorrhoids.<xref ref-type="bibr" rid="article-145193.r5">[5]</xref>&#x000a0;Sclerotherapy remains the gold standard therapeutic intervention for lower extremity superficial varicose veins, reticular veins, and telangiectasia.&#x000a0;</p>
        <p>The treatment of venous insufficiency and varicosities dates back to Galen, Celsus, and Hippocrates.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;However, the modern medical references to sclerotherapy appeared in the 1850s. High infection rates secondary to treatments with perchloride of iron of mercury at that time resulted in the abandonment of sclerosing interventions until the early 1900s with the introduction of hypertonic saline as a sclerosing agent.<xref ref-type="bibr" rid="article-145193.r7">[7]</xref>&#x000a0;Reiner introduced STS as a sclerosing agent in the 1940s, and the modern era of sclerotherapy was born.<xref ref-type="bibr" rid="article-145193.r7">[7]</xref></p>
      </sec>
      <sec id="article-145193.s2" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>Venous varicosities of the lower extremities are large, tortuous veins frequently visible beneath the skin, giving the extremities a lumpy, irregular contour and causing itching, pain, swelling, a feeling of heaviness, and occasionally bleeding.<xref ref-type="bibr" rid="article-145193.r1">[1]</xref> Venous varicosities affect nearly one-third of the population, of which 60% are women.<xref ref-type="bibr" rid="article-145193.r8">[8]</xref><xref ref-type="bibr" rid="article-145193.r9">[9]</xref>&#x000a0; The incidence of venous varicosities increases with age.<xref ref-type="bibr" rid="article-145193.r10">[10]</xref></p>
        <p>Venous varicosities are often related to venous insufficiency of the deep or superficial venous systems or their connecting perforating vessels.<xref ref-type="bibr" rid="article-145193.r10">[10]</xref>&#x000a0;Incompetence of the superficial venous system leads to visible varicosities, while deep venous insufficiency can cause lower extremity edema with subsequent hyperpigmentation, induration, and ulceration of the skin.<xref ref-type="bibr" rid="article-145193.r10">[10]</xref></p>
        <p>Family history is the most&#x000a0;significant&#x000a0;predisposing factor for developing venous varicosities. However, activities or conditions that increase intraabdominal pressure and impede venous blood flow toward the heart, such as obesity, constipation, pregnancy, standing for long periods, and estrogen and progesterone supplementation, promote venous dilatation.<xref ref-type="bibr" rid="article-145193.r10">[10]</xref>&#x000a0;Trauma may damage perforating veins and increase blood flow from the deep to the superficial circulatory system, promoting varicosity formation. Telangiectasias may occur secondary to localized trauma or in response to sun exposure or radiation damage.<xref ref-type="bibr" rid="article-145193.r10">[10]</xref>&#x000a0;</p>
        <p>Approximately 90% of the venous drainage in the&#x000a0;lower extremities is via the deep venous system; incompetence of this system is usually due to insufficient venous valves&#x000a0;that permit inappropriate backflow, increasing pressure on the superficial system and&#x000a0;predisposing to superficial varicosities.<xref ref-type="bibr" rid="article-145193.r10">[10]</xref>&#x000a0;Superficial venous varicosities contain&#x000a0;increased collagen and decreased elastin, resulting in weakness of the vein wall and valves. Increased pressure from incompetent deep veins, especially when standing or walking, causes superficial venous distension.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref>&#x000a0;</p>
        <p>Venous varicosities are tortuous veins that measure greater than 4 to 5 mm in diameter; reticular veins measure from 1 to 4 mm in diameter. Telangiectasias are bluish vessels frequently found branching off reticular veins in fan-shaped arrays; they may be greater than 1 mm in diameter. Spider veins are reddish in color and measure less than 1 mm in diameter. <xref ref-type="bibr" rid="article-145193.r3">[3]</xref><xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;</p>
        <p>Telangiectatic and venous varicosities are signs of venous insufficiency, a process characterized by the reversal of venous blood flow, which predisposes to the development of venous hypertension, an increase in venous diameter, and resultant valvular insufficiency. Incompetent communicating veins cause blood to flow back toward the deep venous system, increasing pressure and inducing dilatation of the superficial veins to accommodate this increased blood flow. The naturally occurring elevation in venous pressure inside the calf-muscle pump during movement of the lower limbs is transmitted directly to the superficial veins and subcutaneous tissues connected with these communicating veins. Telangiectasias also result from increased venous pressure in the superficial vascular system <xref ref-type="bibr" rid="article-145193.r10">[10]</xref>.</p>
        <p>Treating telangiectasias, reticular veins, and venous varicosities requires a multifaceted approach involving medical therapies, lifestyle modifications such as exercise to improve the muscular pumps within the legs, weight loss to decrease central venous pressure, limb elevation, and compression garments which can be knee-high, thigh-high, or full-body.<xref ref-type="bibr" rid="article-145193.r8">[8]</xref>&#x000a0;The classification of venous insufficiency comprises clinical, etiologic, anatomic, and pathologic features (CEAP), as shown in <bold>Table 1.</bold> Invasive treatment is indicated in C2 disease or&#x000a0;greater, with surgical options including vein stripping or ligation, endovascular options such as ablation with radiofrequency devices, thermal or steam damage, or nonsurgical treatments such as sclerotherapy.<xref ref-type="bibr" rid="article-145193.r8">[8]</xref></p>
        <table-wrap id="article-145193.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;CEAP Classification</title>
          </caption>
          <table style="width: 600px; border-color: black;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">
<bold>CEAP Classification</bold>
</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">
<bold>Features</bold>
</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C1</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Reticular veins, telangiectasias, or spider veins of purely cosmetic concern</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C2a</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Asymptomatic varicose veins&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C2b</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Symptomatic varicose veins (itching, pain, thrombosis, bleeding)&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C3</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Edema due to varicose veins&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C4</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Skin changes such as lipodermatosclerosis or hyperpigmentation</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C5</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Healed venous ulcers&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 80px;" rowspan="1" colspan="1">C6</td>
                <td style="width: 377.128px;" rowspan="1" colspan="1">Active venous ulcers</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Sclerosants</bold>
</p>
        <p>The sclerosants commonly employed in current clinical practice can be classified as irritants, osmotic agents, or detergents.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref><xref ref-type="bibr" rid="article-145193.r12">[12]</xref> Sclerosants damage the endothelial cells of the tunica intima and the luminal 300 &#x003bc;m of the tunica media.<xref ref-type="bibr" rid="article-145193.r1">[1]</xref>&#x000a0;Irritants and osmotic sclerosants are directly cytotoxic; detergents are less cytotoxic but disrupt intercellular connections.<xref ref-type="bibr" rid="article-145193.r1">[1]</xref>&#x000a0;In the United States, the most commonly employed sclerosants are the osmotic agent hypertonic saline and the detergents STS and polidocanol.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref></p>
        <p>Foam sclerosants were first described in the 1930s when air was incorporated into a vial of liquid detergent sclerosant via agitation to create a microfoam.<xref ref-type="bibr" rid="article-145193.r7">[7]</xref>&#x000a0;This technique has undergone multiple modifications; the current technique of employing 2 syringes and a multiway stopcock was first described in 1997 by Tesari and Frullini.<xref ref-type="bibr" rid="article-145193.r7">[7]</xref>&#x000a0;Foam sclerotherapy is favored over pure liquid sclerotherapy because foam bubbles increase the surface area of the liquid, prolonging contact with the vessel endothelium&#x000a0;while minimizing the mixing of the sclerosant in the blood.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref><xref ref-type="bibr" rid="article-145193.r13">[13]</xref>&#x000a0;Foam is more viscous, has an exponentially larger surface area,&#x000a0;and allows for treatment to occur with a smaller volume while simultaneously increasing the length of efficacy within the target vein.<xref ref-type="bibr" rid="article-145193.r2">[2]</xref><xref ref-type="bibr" rid="article-145193.r14">[14]</xref>&#x000a0;Foam induces a vasospastic response&#x000a0;that apposes vessel walls&#x000a0;and increases the likelihood that the vein remains obliterated.<xref ref-type="bibr" rid="article-145193.r2">[2]</xref>&#x000a0;</p>
        <p>The majority of sclerotherapy procedures are performed using room air; pure CO<sub>2</sub> and 70/30 mixtures of CO<sub>2</sub>/O<sub>2</sub>&#x000a0;may be utilized.&#x000a0;A ratio of 1-part liquid to 4- or 5-part gas is the most stable.<xref ref-type="bibr" rid="article-145193.r15">[15]</xref>&#x000a0;Carbon dioxide offers several benefits over room air: it forms smaller bubbles and dissipates more quickly, increasing the surface area of endothelial contact and subsequent fibrosis, while dissolving more readily into the blood and decreasing adverse effects.<xref ref-type="bibr" rid="article-145193.r13">[13]</xref></p>
        <p>
<bold>Irritant Sclerosants</bold>
</p>
        <p>Irritants are corrosive agents&#x000a0;that destroy cellular membranes and lead to vessel fibrosis.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;Typical irritants are ethanol, phenol, and polyiodinated iodine; polyiodinated iodines cause full-thickness vessel destruction. The historically but no longer utilized agents, perchloride of iron or mercury, are also irritants.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref></p>
        <p>
<bold>Osmotic&#x000a0;Sclerosants</bold>
</p>
        <p>Osmotic sclerosants destroy cells by promoting rapid diffusion of intracellular fluid into the vessel, resulting in cellular dehydration and membrane disruption.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;The most commonly utilized osmotic sclerosants are 23% hypertonic saline (HTS)&#x000a0;and glycerin.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref><xref ref-type="bibr" rid="article-145193.r16">[16]</xref></p>
        <p>Hypertonic saline is an osmotic agent most commonly utilized when treating hyponatremia and cerebral edema.&#x000a0;HTS is available in 3% or 23% concentrations; 23% HTS is used when treating varicose veins. The use of 23% HTS initially fell out of favor due to&#x000a0;its adverse effect of extravasation necrosis, but its use was revived in the 1970s with the advent of fine-gauge, disposable syringes.<xref ref-type="bibr" rid="article-145193.r17">[17]</xref>&#x000a0;This osmotic agent uses the concentration gradient between the endothelial cell and the intravascular space&#x000a0;to cause fibrosis by denaturing the endothelial cell membrane. However, HTS is easily diluted in blood, rendering it ineffective unless a sufficient solution is injected to displace blood from the treated vein.<xref ref-type="bibr" rid="article-145193.r17">[17]</xref>&#x000a0;HTS has a low toxicity profile and poses virtually&#x000a0;no risk of anaphylaxis. However, the injection of HTS can cause localized transient pain, muscle cramping, or hyperpigmentation.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref></p>
        <p>Glycerin (glycerol;&#x000a0;1,2,3-propanetriol) is a potent osmotic agent most frequently utilized to treat intracranial hypertension.<xref ref-type="bibr" rid="article-145193.r16">[16]</xref>&#x000a0;The sclerosing effects of glycerol were first elucidated in 1925 by Jausion et al; glycerin induces mild endosclerosis within 45 minutes of administration.<xref ref-type="bibr" rid="article-145193.r16">[16]</xref>&#x000a0;</p>
        <p>
<bold>Detergent Sclerosants</bold>
</p>
        <p>Detergent sclerosants disrupt cell membranes&#x000a0;via protein denaturation.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;Detergent sclerosants also form micelles at certain concentrations and will form a foam when mixed with gas. Unlike other sclerosants, detergents in liquid and foam configurations cause endothelial damage within&#x000a0;several minutes after administration; cellular injury can spread away from the injection site.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;Detergent sclerosants employed during sclerotherapy include STS, polidocanol, morrhuate sodium, and ethanolamine oleate.&#x000a0;</p>
        <p>STS is a small, synthetic organic sodium salt; 2% benzyl alcohol is added to the formulation for anesthetic purposes in medical use.<xref ref-type="bibr" rid="article-145193.r12">[12]</xref>&#x000a0;STS is a clear, nonviscous solution that evenly distributes within the blood following injection and rapidly clears as it attaches to red blood cells and causes hemolysis <xref ref-type="bibr" rid="article-145193.r12">[12]</xref>.&#x000a0;&#x000a0;</p>
        <p>Polidocanol is a synthetic polyethylene glycol initially marketed as a local anesthetic.<xref ref-type="bibr" rid="article-145193.r7">[7]</xref> However, injection of polidocanol was found to cause venous sclerosis. While it is still used as a topical anesthetic, its primary use is as a sclerosant.<xref ref-type="bibr" rid="article-145193.r18">[18]</xref> Polidocanol for sclerotherapy is dissolved in distilled water and ethanol to achieve a 5% concentration that facilitates micelle formation.<xref ref-type="bibr" rid="article-145193.r12">[12]</xref></p>
        <p>Polidocanol and STS come in various concentrations, each with recommendations for the size of the vein that can be treated (see <bold>Table 2.</bold> Size Requirements for STS and Polidocanol Based on Concentration). The incidence of allergic or anaphylactic reaction following STS or polidocanol injection is less than 1%.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref>The 3% STS foam&#x000a0;is more potent than 3% Polidocanol, rendering 3% STS foam more appropriate for use on larger veins. Polidocanol is more appropriate for telangiectasias or reticular veins due to&#x000a0;its anesthetic properties and decreased risk of thrombophlebitis.<xref ref-type="bibr" rid="article-145193.r19">[19]</xref></p>
        <table-wrap id="article-145193.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Size requirements for STS and Polidocanol based on concentration.</title>
          </caption>
          <table style="width: 757px; border-color: black;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">Concentration</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Vein type and diameter&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">STS liquid 0.1%-0.3%</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Telangiectatic veins 0.2-1 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">STS liquid 0.5%-1%</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Uncomplicated varicose veins 2-4 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">STS foam 0.25%-1% (1:4 ratio)</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Large reticular and varicose veins 3-6 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">STS foam 3% (1:4 ratio)</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Great saphenous vein or veins up to 10 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">Polidocanol 0.5%</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Telangiectasias &#x0003c;1 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">Polidocanol 1%</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Veins 1-2 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">Polidocanol 2%</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Reticular and varicose veins 2-4 mm</td>
              </tr>
              <tr>
                <td style="width: 260.038px;" rowspan="1" colspan="1">Polidocanol 3%</td>
                <td style="width: 488.962px;" rowspan="1" colspan="1">Larger veins 4-8 mm</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-145193.s3" sec-type="Indications">
        <title>Indications</title>
        <p>Sclerotherapy techniques are indicated in the treatment of venous varicosities and certain hemorrhoids. The sclerosants utilized in these therapeutic interventions vary.</p>
        <p>Liquid or foam sclerotherapy is an indicated treatment for cosmetically distressing or disturbing varicose veins, spider veins, reticular veins, and telangiectasias. These therapies are also employed when treating saphenous vein reflux, enlarged tributary and perforator veins, and vascular malformations.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref>&#x000a0;Sclerotherapy can also be used to treat smaller collateral veins not amenable to stab phlebectomy or ablation.</p>
        <p>A meta-analysis of foam sclerotherapy as a treatment for venous ulceration or C5-C6 venous insufficiency revealed that foam sclerotherapy may be superior to compression therapy alone. However, this meta-analysis evaluated a few markedly heterogeneous studies; more research is needed.<xref ref-type="bibr" rid="article-145193.r20">[20]</xref></p>
        <p>Utilizing ultrasound guidance during sclerotherapy for venous insufficiency provides a simple, efficacious, targeted method&#x000a0;to treat deep venous insufficiency.<xref ref-type="bibr" rid="article-145193.r21">[21]</xref>&#x000a0;Studies have reported extremely high satisfaction rates with ultrasound-guided sclerotherapy (UGS); one study reported that 100% of patients were satisfied with the degree of treatment, and more than 90% reported improved quality of life and appearance of the treated limb.[19] Ultrasound-guided sclerotherapy may be appropriate for any patient but is particularly useful when treating patients with obesity,&#x000a0;insufficiency of the great saphenous vein, and whose comorbidities preclude more invasive surgery.<xref ref-type="bibr" rid="article-145193.r13">[13]</xref><xref ref-type="bibr" rid="article-145193.r21">[21]</xref><xref ref-type="bibr" rid="article-145193.r22">[22]</xref></p>
        <p>Sclerotherapy is also indicated when treating patients with symptomatic hemorrhoids, active bleeding, risks of major bleeding, and those with HIV or AIDS. Phenol in almond oil and 3% polidocanol are the sclerosants recommended for treating grades 1 through 3 hemorrhoids; aluminum potassium sulfate and tannic acid (ALTA)are recommended for treating grades 2 through 4 hemorrhoids.<xref ref-type="bibr" rid="article-145193.r5">[5]</xref></p>
      </sec>
      <sec id="article-145193.s4" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are several absolute and relative contraindications to sclerotherapy for venous varicosities; in patients for whom sclerotherapy is contraindicated, other treatment options, such as stab phlebectomy, should be considered.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref> The contraindications for patients with venous varicosities differ from those with hemorrhoids.</p>
        <p>Absolute contraindications to sclerotherapy for the treatment of venous varicosities include but are not limited to specific sclerosant allergy, current systemic infection or that localized to the treatment area, and a personal history of deep venous thrombosis, severe peripheral arterial disease, advanced collagen vascular diseases, or cardiovascular or neurologic events following sclerosant injection.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref><xref ref-type="bibr" rid="article-145193.r6">[6]</xref><xref ref-type="bibr" rid="article-145193.r23">[23]</xref></p>
        <p>Relative contraindications to sclerotherapy for the treatment of venous varicosities include severely impaired mobility and a personal history of a marked allergic diathesis, asthma, severe deep venous incompetence, or thrombophilia. Sclerotherapy may also be relatively contraindicated in patients who are currently pregnant or breastfeeding.<xref ref-type="bibr" rid="article-145193.r19">[19]</xref><xref ref-type="bibr" rid="article-145193.r11">[11]</xref>&#x000a0;Visual disturbances and transient ischemic attacks, possibly due to paradoxical emboli, have been reported following foam sclerotherapy in patients with a patent foramen ovale.<xref ref-type="bibr" rid="article-145193.r1">[1]</xref><xref ref-type="bibr" rid="article-145193.r11">[11]</xref>&#x000a0;Large varices may be a relative contraindication to sclerotherapy due to the increased risk of recanalization.</p>
        <p>Contraindications to the use of sclerotherapy in the treatment of hemorrhoids include thrombosed hemorrhoids and a personal history of asthma, specific sclerosant allergy, thrombophilia, inflammatory bowel disease, and cardiac, renal, or hepatic comorbidities.<xref ref-type="bibr" rid="article-145193.r5">[5]</xref></p>
      </sec>
      <sec id="article-145193.s5" sec-type="Equipment">
        <title>Equipment</title>
        <p>The equipment required to perform sclerotherapy typically includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Needle, 30-gauge or smaller</p>
          </list-item>
          <list-item>
            <p>Multiple 5-mL syringes</p>
          </list-item>
          <list-item>
            <p>Sclerosant of choice</p>
          </list-item>
          <list-item>
            <p>Local anesthetic</p>
          </list-item>
          <list-item>
            <p>Gauze dressings</p>
          </list-item>
          <list-item>
            <p>Compressive bandages</p>
          </list-item>
          <list-item>
            <p>Ultrasound (if performing ultrasound-guided sclerotherapy)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145193.s6" sec-type="Personnel">
        <title>Personnel</title>
        <p>The personnel required to perform sclerotherapy in an office-based setting typically include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary clinician trained in sclerotherapy</p>
          </list-item>
          <list-item>
            <p>Assistant</p>
          </list-item>
        </list>
        <p>The personnel required to perform sclerotherapy in a&#x000a0;hospital-based setting, perhaps as part of a more complex procedure, typically include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary clinician trained in sclerotherapy</p>
          </list-item>
          <list-item>
            <p>Surgical technician or operating room nurse</p>
          </list-item>
          <list-item>
            <p>Circulating or operating room nurse</p>
          </list-item>
          <list-item>
            <p>Anesthesia personnel</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-145193.s7" sec-type="Preparation">
        <title>Preparation</title>
        <p>The patient and primary clinician should engage in shared decision-making before the procedure to ensure an understanding of the possibility of adverse events and the risk of cosmetic complications such as hyperpigmentation and telangiectatic matting. These risks are increased in patients taking combined oral contraceptives, disulfiram, or minocycline.<xref ref-type="bibr" rid="article-145193.r23">[23]</xref></p>
        <p>Sclerotherapy is typically performed with the patient in the supine or seated position, as dictated by optimum visualization of the target vessels. The identified procedural areas should be prepped and draped in a sterile fashion. If ultrasound guidance is employed, the machine should be set to vascular mode. Detergent sclerosants to be used as foam should be combined with air employing the Tessari or double-syringe technique (see&#x000a0;<bold>Figure.</bold>&#x000a0;Schematic of Tessari Technique).<xref ref-type="bibr" rid="article-145193.r24">[24]</xref><xref ref-type="bibr" rid="article-145193.r15">[15]</xref></p>
      </sec>
      <sec id="article-145193.s8" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>Sclerosant injection should be carried out in a &#x0201c;downstream&#x0201d; fashion from the largest to the smallest vessels, such that the sclerosant will flow from the injection site into other target veins.<xref ref-type="bibr" rid="article-145193.r3">[3]</xref><xref ref-type="bibr" rid="article-145193.r17">[17]</xref>&#x000a0;The entire superficial venous system of each leg should be treated in one setting to avoid recanalization or hyperpigmentation due to the extravasation of erythrocytes from the damaged vessel.</p>
        <p>Cannulate the target vein with a 30-gauge or smaller needle; confirm correct intravascular placement using aspiration.<xref ref-type="bibr" rid="article-145193.r2">[2]</xref><xref ref-type="bibr" rid="article-145193.r17">[17]</xref>&#x000a0;Once intravascular placement is confirmed, inject only enough sclerosant to displace the blood from the vessel.<xref ref-type="bibr" rid="article-145193.r3">[3]</xref>&#x000a0;For reticular veins, spider veins, and telangiectasias, inject only enough sclerosant to induce blanching of the system; blanching confirms successful treatment.<xref ref-type="bibr" rid="article-145193.r17">[17]</xref>&#x000a0;Using the lowest necessary volume and concentration&#x000a0;for vessel injection reduces the risk of initiating new telangiectasias around the treated area.&#x000a0;</p>
        <p>Patients should remain supine or seated for several minutes following sclerosant injection. The treated extremity should be wrapped with a compressive dressing, or compression stockings should be worn. Dressings and stocking should not be removed for 7 days to promote compression of the treated vessels. Applying compression immediately following sclerotherapy minimizes thrombus formation. Patients should be encouraged to ambulate with the compressive wraps or garments in place.</p>
      </sec>
      <sec id="article-145193.s9" sec-type="Complications">
        <title>Complications</title>
        <p>Localized adverse effects of sclerotherapy for venous varicosities include but are not limited to pain with or following sclerosant injection, erythema, edema, pruritus, ulceration, increased hair growth, and telangiectatic matting characterized by the appearance of a complex of fine, red veins in the treated area.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref><xref ref-type="bibr" rid="article-145193.r13">[13]</xref>&#x000a0;Pain during sclerosant injection is especially common with HTS and glycerin.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref> Approximately 30% of patients may experience skin hyperpigmentation or discoloration from hemosiderin deposition 6 to 8 weeks following sclerotherapy.<xref ref-type="bibr" rid="article-145193.r11">[11]</xref>&#x000a0;A systematic review of patients who underwent sclerotherapy with polidocanol demonstrated that hyperpigmentation was more common with a higher sclerosant concentration or treatment focused on superficial venous systems such as the epifascial vessels.<xref ref-type="bibr" rid="article-145193.r25">[25]</xref></p>
        <p>Systemic adverse effects of sclerotherapy include chest tightness, visual disturbances, transient ischemic attacks, dizziness, and migraine headaches; headaches are more likely to occur in patients with a history of migrainous events.<xref ref-type="bibr" rid="article-145193.r13">[13]</xref>&#x000a0;These adverse effects occur more frequently following unintentional injection of the deep venous system and ultrasound-guided treatment of the great saphenous vein.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref><xref ref-type="bibr" rid="article-145193.r13">[13]</xref></p>
        <p>The incomplete destruction of the target vessel may lead to recanalization and the need for additional procedures; prolonged compression of the treated limb assists healing and minimizes the risk of recanalization.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;A systematic review noted no significant differences in the rate of complications or optimal outcomes between foam and liquid sclerotherapy.<xref ref-type="bibr" rid="article-145193.r1">[1]</xref></p>
        <p>The osmotic agents HTS and glycerin carry an increased risk for local tissue damage and ulceration if the solution extravasates or is injected into an arteriole.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;Intraarterial injection of HTS or glycerin can potentially&#x000a0;induce acute limb ischemia that requires amputation.<xref ref-type="bibr" rid="article-145193.r26">[26]</xref>&#x000a0;Additionally, glycerin may cause mild hematuria; adding a chromated alum to the glycerol molecule can mitigate this adverse effect. This modification increases the potency of the sclerosant.<xref ref-type="bibr" rid="article-145193.r16">[16]</xref></p>
        <p>The most common complication of hemorrhoid sclerotherapy is an easily treatable localized infection; more severe infections and sepsis have been reported. Additionally, improper or excessive sclerosant injection may lead to surrounding tissue necrosis and complications such as rectovaginal fistulae.<xref ref-type="bibr" rid="article-145193.r5">[5]</xref></p>
      </sec>
      <sec id="article-145193.s10" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Sclerotherapy is a clinically significant treatment modality for venous varicosities, offering a minimally invasive approach with substantial therapeutic benefits via a controlled thrombophelbitic reaction.&#x000a0;Sclerotherapy is effective in treating varicose veins, spider veins, and telangiectasia in a short amount of time. Injection sclerotherapy provides notable cosmetic improvement by reducing the appearance of unsightly veins and enhancing patients' confidence and quality of life.&#x000a0;Moreover, injection sclerotherapy alleviates symptoms associated with venous insufficiency, such as pain, swelling, and discomfort, leading to improved overall vascular health.</p>
        <p>Injection sclerotherapy is versatile, offers primary or adjunctive therapeutic options, is applicable in various settings, and can be performed on an outpatient basis without the need for extensive recovery time. Its minimally invasive nature makes it an attractive option for patients averse to surgery or for whom surgery is contraindicated. Furthermore, advancements in sclerosing agents and techniques have enhanced efficacy and safety, contributing to the widespread use of injection sclerotherapy in managing venous varicosities.</p>
        <p>Overall, sclerotherapy offers cosmetic enhancement and symptomatic relief, making it an inherently valuable treatment option for patients with venous&#x000a0;disease.</p>
      </sec>
      <sec id="article-145193.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with venous&#x000a0;varicosities often require multimodality treatments ranging from compression therapy to surgical intervention to&#x000a0;achieve optimal results.<xref ref-type="bibr" rid="article-145193.r6">[6]</xref>&#x000a0;Asymptomatic patients may wish only to improve cosmesis; symptomatic patients may additionally desire symptom relief. Patients with venous varicosities frequently present to various healthcare providers, including primary care providers, plastic surgeons, dermatologists, or vascular surgeons. If the venous disease has resulted in ulceration, wound care specialists may be involved. A comprehensive understanding of the multimodal therapies employed in venous varicosity treatment is needed to provide optimal patient care.</p>
        <p>The Cochrane database reviews several available interventions for treating venous varicosities, including laser or radiofrequency endovenous ablation therapy, ultrasound-guided foam sclerotherapy, and traditional surgery. Low-to-moderate&#x02013;quality evidence suggests that 1-year recanalization rates are lower following endovenous ablation therapy than conventional surgery. However, the review could not&#x000a0;determine whether ultrasound-guided foam sclerotherapy was superior to traditional surgery.<xref ref-type="bibr" rid="article-145193.r27">[27]</xref>&#x000a0;</p>
        <p>Achieving optimal outcomes following injection sclerotherapy&#x000a0;necessitates a collaborative interprofessional approach that engages in shared decision-making with patients, ensuring alignment with individual preferences, understanding potential risks, and establishing realistic treatment expectations. Effective communication among team members and patients enhances treatment efficacy and patient satisfaction. Clinical staff, including nurses, assistants, and pharmacists, play a critical role in patient education, providing preprocedural guidance and postprocedural care instructions.</p>
        <p>An interprofessional approach and shared decision-making ultimately foster patient-centered care, optimizing injection sclerotherapy outcomes. This approach ensures comprehensive evaluation, personalized treatment strategies, and patient empowerment, enhancing treatment adherence, improved outcomes, and overall patient satisfaction.</p>
      </sec>
      <sec id="article-145193.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=145193&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=145193">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/145193/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=145193">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-145193.s13">
        <fig id="article-145193.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Schematic of Tessari Technique UpToDate https://ykhoa.org/d/image.htm?imageKey=SURG/79497</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Screen__Shot__2023-09-08__at__3.13.46__PM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-145193.s14">
        <title>References</title>
        <ref id="article-145193.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de &#x000c1;vila Oliveira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Riera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vasconcelos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Baptista-Silva</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Injection sclerotherapy for varicose veins.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Dec</month>
            <day>10</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD001732</fpage>
            <pub-id pub-id-type="pmid">34883526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palm</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Guiha</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Foam sclerotherapy for reticular veins and nontruncal varicose veins of the legs: a retrospective review of outcomes and adverse effects.</article-title>
            <source>Dermatol Surg</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>36 Suppl 2</volume>
            <fpage>1026</fpage>
            <page-range>1026-33</page-range>
            <pub-id pub-id-type="pmid">20590709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>My sclerotherapy technique for telangiectasia and reticular veins.</article-title>
            <source>Dermatol Surg</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>36 Suppl 2</volume>
            <fpage>1040</fpage>
            <page-range>1040-5</page-range>
            <pub-id pub-id-type="pmid">20590711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sadick</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Consensus for sclerotherapy.</article-title>
            <source>Dermatol Surg</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>1309</fpage>
            <page-range>1309-18</page-range>
            <pub-id pub-id-type="pmid">25418805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sclerotherapy in Hemorrhoids.</article-title>
            <source>Indian J Surg</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-232</page-range>
            <pub-id pub-id-type="pmid">35469212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Worthington-Kirsch</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Injection sclerotherapy.</article-title>
            <source>Semin Intervent Radiol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-17</page-range>
            <pub-id pub-id-type="pmid">21326695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myers</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A history of injection treatments - II sclerotherapy.</article-title>
            <source>Phlebology</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-310</page-range>
            <pub-id pub-id-type="pmid">30336757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chwa&#x00142;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Szczeklik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Szczeklik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aleksiejew-Kleszczy&#x00144;ski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jagielska-Chwa&#x00142;a</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Varicose veins of lower extremities, hemodynamics and treatment methods.</article-title>
            <source>Adv Clin Exp Med</source>
            <year>2015</year>
            <season>Jan-Feb</season>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-14</page-range>
            <pub-id pub-id-type="pmid">25923081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Gkogkolou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goerge</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sclerotherapy of varicose veins in dermatology.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2014</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>391</fpage>
            <page-range>391-3</page-range>
            <pub-id pub-id-type="pmid">24797742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Bergan</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of varicose veins: a review.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3 Pt 1</issue>
            <fpage>393</fpage>
            <page-range>393-413; quiz 414-6</page-range>
            <pub-id pub-id-type="pmid">8077464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrews</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Ambulatory Phlebectomy and Sclerotherapy as Tools for the Treatment of Varicose Veins and Telangiectasias.</article-title>
            <source>Semin Intervent Radiol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-166</page-range>
            <pub-id pub-id-type="pmid">34108801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wildemore</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins.</article-title>
            <source>Dermatol Surg</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>631</fpage>
            <page-range>631-5; discussion 635</page-range>
            <pub-id pub-id-type="pmid">15996411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peterson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study.</article-title>
            <source>Phlebology</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-6</page-range>
            <pub-id pub-id-type="pmid">21926097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tremaine</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Friedmann</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Foam sclerotherapy for reticular veins of the dorsal hands: a retrospective review.</article-title>
            <source>Dermatol Surg</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>892</fpage>
            <page-range>892-8</page-range>
            <pub-id pub-id-type="pmid">25022711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peterson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>An investigation into the influence of various gases and concentrations of sclerosants on foam stability.</article-title>
            <source>Dermatol Surg</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-7</page-range>
            <pub-id pub-id-type="pmid">21199095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leach</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins.</article-title>
            <source>Dermatol Surg</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>612</fpage>
            <page-range>612-4; discussion 615</page-range>
            <pub-id pub-id-type="pmid">12786704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spurrier</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sclerotherapy for leg telangiectasia--a blinded comparative trial of polidocanol and hypertonic saline.</article-title>
            <source>Dermatol Surg</source>
            <year>1999</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>381</fpage>
            <page-range>381-5; discussion 385-6</page-range>
            <pub-id pub-id-type="pmid">10469077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffy</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Sclerosants: a comparative review.</article-title>
            <source>Dermatol Surg</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>36 Suppl 2</volume>
            <fpage>1010</fpage>
            <page-range>1010-25</page-range>
            <pub-id pub-id-type="pmid">20590708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ockelford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs.</article-title>
            <source>Dermatol Surg</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-12</page-range>
            <pub-id pub-id-type="pmid">14692919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joyce</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>De Freitas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Tubassam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Ultrasound-guided foam sclerotherapy as a therapeutic modality in venous ulceration.</article-title>
            <source>Surgeon</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>e206</fpage>
            <page-range>e206-e213</page-range>
            <pub-id pub-id-type="pmid">34629303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrett</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ockelford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Microfoam ultrasound-guided sclerotherapy treatment for varicose veins in a subgroup with diameters at the junction of 10 mm or greater compared with a subgroup of less than 10 mm.</article-title>
            <source>Dermatol Surg</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>1386</fpage>
            <page-range>1386-90</page-range>
            <pub-id pub-id-type="pmid">15522019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breu</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Guggenbichler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wollmann</surname>
                <given-names>JC</given-names>
              </name>
              <collab>Second European Consensus Meeting on Foam Sclerotherapy</collab>
            </person-group>
            <article-title>Duplex ultrasound and efficacy criteria in foam sclerotherapy from the 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany.</article-title>
            <source>Vasa</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-5</page-range>
            <pub-id pub-id-type="pmid">18512547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parsi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>De Maeseneer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caprini</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cavezzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Gianesini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gillet</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Grondin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guex</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hamel-Desnos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mosti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Orrego</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Partsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rabe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Raymond-Martimbeau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schadeck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simkin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tessari</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thibault</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Ulloa</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Whiteley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zimmet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vuong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sclerotherapy of lower limb veins: Indications, contraindications and treatment strategies to prevent complications - A consensus document of the International Union of Phlebology-2023.</article-title>
            <source>Phlebology</source>
            <year>2023</year>
            <month>May</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>205</fpage>
            <page-range>205-258</page-range>
            <pub-id pub-id-type="pmid">36916540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hummel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leaviss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Everson-Hock</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michaels</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation.</article-title>
            <source>Health Technol Assess</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>48</issue>
            <fpage>i</fpage>
            <page-range>i-xvi, 1-141</page-range>
            <pub-id pub-id-type="pmid">24176098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bossart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daneluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cazzaniga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramelet</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Uthoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seyed Jafari</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hunger</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Heidemeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Willenberg</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>274</fpage>
            <page-range>274-283</page-range>
            <pub-id pub-id-type="pmid">36196455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yiannakopoulou</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose Veins.</article-title>
            <source>Pharmacology</source>
            <year>2016</year>
            <volume>98</volume>
            <issue>1-2</issue>
            <fpage>62</fpage>
            <page-range>62-9</page-range>
            <pub-id pub-id-type="pmid">27104778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-145193.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paravastu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Nov</month>
            <day>29</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD010878</fpage>
            <pub-id pub-id-type="pmid">27898181</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
